ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute ...
Erythropoietin, a treatment for newborns with critically low levels of oxygen or blood supply to the brain at birth, does not prevent death or disability, according to a new multinational study. The ...
Whole-body hypothermia within hours of birth failed to improve outcomes in preterm infants less than 36 weeks' gestational age with hypoxic-ischemic encephalopathy. Death or moderate or severe ...
ReAlta Life Sciences said it is presenting new data from its hypoxic ischemic encephalopathy (HIE) program at the Pediatric Academic Societies Annual Meeting, taking place in Honolulu, Hawaii, from ...
NORFOLK, Va.--(BUSINESS WIRE)--ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback